AIOSYN
14.3.2023 13:01:37 CET | Business Wire | Press release
Aiosyn, a software company that develops AI-powered pathology software, has launched its first product that assists digital pathology labs across research, diagnostics and pharma to improve their quality control (QC) process. AiosynQC is an AI-powered algorithm that automatically scans for the most common artifacts that occur during the heterogeneous pre-analytical process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005006/en/
Out-of-focus regions of an H&E stained slide image, blurry and difficult to read, are identified and highlighted with Aiosyn's automated quality control powered by AI. (Photo: Business Wire)
The algorithm of AiosynQC is trained on hematoxylin and eosin (H&E) stained slides. The product helps labs to ensure that only high-quality images are used by pathologists, technicians, and researchers. It can flag cases before presentation to a pathologist, thereby improving the efficiency of the digital pathology workflow by reducing the time that is currently used to manually check for artifacts in whole slide images.
AiosynQC is a modular and flexible software offered as a service solution that can be integrated into existing digital pathology software and deployed through the cloud or on-premise installation. The automated QC is the first product in Aiosyn’s workflow solutions suite. It will be part of a portfolio of deep learning algorithms currently in development for different pathologies for which there is a clear need to improve diagnostic precision and quality.
“AiosynQC will be an important foundational layer and we believe that AI-powered workflow solutions are the entry point for the use and adoption of computational pathology algorithms” according to Patrick de Boer, CEO of Aiosyn.
More information about AiosynQC can be found here.
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice. More about Aiosyn can be found here.
AiosynQC
AiosynQC can only be used in the European Union and the United Kingdom. In the EU and the UK, AiosynQC is not considered a medical device under European IVDR and UK MDR 2002 legislation, respectively. AiosynQC is not intended to be used as an accessory to, nor is it necessary to be used in combination with, any AI or other medical devices to specifically enable them to meet their intended purpose or directly assist in their functionality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELLENiQ ENERGY and Chevron Sign Offshore Concession Agreements for Hydrocarbon Exploration and Production with the Hellenic Republic16.2.2026 19:07:00 CET | Press release
Marking a New Milestone in HELLENiQ ENERGY’s Upstream Portfolio HELLENiQ ENERGY, in collaboration with Chevron, signed today the Lease Agreements with the Hellenic Republic for the exploration of four offshore blocks located south of Crete and the Peloponnese, marking a significant milestone for Greece’s upstream development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216381183/en/ Snapshot from the signing of the lease agreements at the Maximos Mansion, attended by Prime Minister Kyriakos Mitsotakis. From left: Stavros Papastavrou, Minister of Environment and Energy; Andreas Shiamishis, CEO of HELLENiQ ENERGY; Gavin Lewis, VP Global New Ventures at Chevron; and Aristofanis Stefatos, CEO of HEREMA The successful consortium, with Chevron at 70% interest and being the Operator and HELLENiQ ENERGY at 30% interest, was selected following a competitive international tender launched by the Greek State in 2025. The four offs
Nexo Returns to the U.S.16.2.2026 17:00:00 CET | Press release
Nexo is relaunching its flagship Yield, Exchange, Loyalty, and Credit Lines in the United States. Nexo today announced its formal return to the United States market in 2026. The company’s official U.S. relaunch is being executed in partnership with regulated partners, providing a U.S.-compliant framework for the company’s investment and credit product offerings. Digital asset trading infrastructure is provided by Bakkt, a publicly listed U.S.-based digital asset platform purpose-built to support institutional risk management and compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216234514/en/ Nexo is relaunching its flagship Yield, Exchange, Loyalty, and Credit Lines in the United States. Nexo’s renewed presence in the United States follows a period of deliberate recalibration and reflects the company’s long-term commitment to operating in markets where regulatory frameworks are evolving, institutional standards a
TRU Simulation’s Full Flight Simulator for the Cessna Citation Ascend Achieves FAA Qualification, Expanding Advanced Training for Midsize Jet Pilots16.2.2026 16:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation, announced today its Full Flight Simulator (FFS) for the Cessna Citation Ascend has achieved Federal Aviation Administration (FAA) Level D qualification. This milestone significantly enhances advanced training options for midsize jet pilots, delivering a highly immersive and true-to-life training environment on the recently FAA certified Citation Ascend. European Union Aviation Safety Agency (EASA) qualification is anticipated in 2026, further extending the simulator’s global reach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216456292/en/ TRU Simulation’s Full Flight Simulator for the Cessna Citation Ascend achieves FAA qualification, expanding advanced training for midsize jet pilots “Pilots deserve training capabilities that reflect the advanced technology and performance that the Citation Ascend brings to the mid
AIT Worldwide Logistics Announces Strategic Partnership With Greenbriar Equity Group16.2.2026 15:03:00 CET | Press release
Agreement supports continuity, accelerating next phase of AIT’s growth plan Supply chain solutions leader AIT Worldwide Logistics (“AIT”) has entered into a definitive agreement to partner with Greenbriar Equity Group, L.P. (“Greenbriar”) in support of the global freight forwarder’s next chapter of growth. Financial terms of the private transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216984391/en/ AIT Worldwide Logistics' strategic partnership with Greenbriar Equity Group represents one of the largest private acquisitions ever in the global freight forwarding sector. The deal marks the culmination of five successful years with The Jordan Company, L.P. (“TJC”). TJC, alongside key members of AIT’s executive leadership team, will remain invested in the company. Over the course of the company’s relationship with TJC, AIT has dramatically expanded its global footprint, acquired 14 businesses, and
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials16.2.2026 14:00:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are scheduled for release on February 17th at 6:30 am ET, followed by a webinar hosted by Compass management at 8:00 am ET. Live Webcast Compass management will host a live audio webcast on February 17th at 8:00 am ET. The webcast will be accessible at this link: https://lifescievents.com/event/hz02j0rpw/ A replay of the webcast will be accessible for 30 days following the event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom